Luisa M Cardenas, Sunita Ghosh, Antonio Finelli, Lori Wood, Christian Kollmannsberger, Naveen Basappa, Jeffrey Graham, Daniel Heng, Georg Bjarnason, Denis Soulières, Dominick Bossé, Vincent Castonguay, Ramy Saleh, Simon Tanguay, Bimal Bhindi, Rodney H Breau, Frederic Pouliot, Aly-Khan A Lalani
PURPOSE: Standard-of-care therapies for metastatic renal cell carcinoma (mRCC) have greatly evolved. However, the availability of emerging options in global health care systems can vary. We sought to describe the integration and usage of systemic therapies for mRCC in Canada since 2011. METHODS: We included patients with mRCC enrolled in the Canadian Kidney Cancer Information System, a prospective cohort of patients from 14 Canadian academic centers, who received systemic therapy from January 1, 2011, to December 31, 2021...
September 2023: JCO global oncology